Olfactory Function in Patients With Sinonasal Diseases: A Multicenter Observational Study
Olfactory Profile of Patients With Sinonasal Diseases: A Multicenter Cross-Sectional Observational Study in Brazil
This multicenter, cross-sectional observational study aims to characterize olfactory function in patients with sinonasal diseases and investigate its associations with disease severity, clinical characteristics, and inflammatory markers. Olfactory function will be assessed using the MultiScent-20 digital odor identification test. Additional assessments will include sinonasal symptom severity, quality of life, endoscopic and radiological findings, and clinical and laboratory markers suggestive of type 2 inflammation. Healthy volunteers without olfactory complaints will serve as a comparison group. The study is expected to enroll 3,800 participants across participating centers in Brazil.
研究概览
地位
详细说明
This is a multicenter, cross-sectional observational study conducted in Brazilian outpatient otolaryngology settings. The study aims to investigate olfactory function in patients with chronic rhinosinusitis and other sinonasal diseases and to explore its associations with clinical manifestations, disease severity, and inflammatory characteristics.
Olfactory function will be objectively assessed using the MultiScent-20 digital odor identification test, which provides a score ranging from 0 to 20, with higher scores indicating better olfactory performance. Participants will undergo a single study assessment.
Clinical data will include sinonasal symptoms, SNOT-22 scores, visual analog scale ratings, nasal polyp scores, previous sinonasal surgeries, relevant comorbidities, and alcohol intolerance. Laboratory, histopathological, and imaging findings obtained during routine clinical care within the predefined eligibility window will be collected when available.
Criteria suggestive of type 2 inflammation will be evaluated using predefined clinical and laboratory characteristics. Missing clinical or laboratory information will not constitute an exclusion criterion. Analyses involving individual variables will include participants with the corresponding available data, whereas the total count of type 2 inflammatory criteria will be calculated only when all eight criteria have been assessed.
A comparison group of healthy volunteers without olfactory complaints will also be included. No therapeutic intervention will be administered as part of this observational study.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Gustavo Subtil M. Freire, MSc
- 电话号码:+55 61 2028-5000
- 邮箱:gustavo.freire@ebserh.gov.br
学习地点
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、巴西
- 招聘中
- Hospital Universitário Professor Edgard Santos (HUPES)
-
-
Federal District
-
Brasília、Federal District、巴西
- 招聘中
- Hospital Universitário de Brasília (HUB)
-
-
Goiás
-
Goiânia、Goiás、巴西
- 招聘中
- Hospital das Clínicas da UFG
-
-
Paraná
-
Curitiba、Paraná、巴西
- 招聘中
- Hospital IPO - sede Água Verde
-
-
Pernambuco
-
Recife、Pernambuco、巴西
- 招聘中
- Hospital das Clínicas da UFPE
-
-
Piauí
-
Teresina、Piauí、巴西
- 招聘中
- Hospital Getúlio Vargas (HGV)
-
-
Rio Grande do Sul
-
Canoas、Rio Grande do Sul、巴西
- 招聘中
- Hospital Universitário Canoas
-
Porto Alegre、Rio Grande do Sul、巴西
- 招聘中
- Hospital de Clínicas de Porto Alegre (HCPA)
-
-
Rio de Janeiro
-
Rio de Janeiro、Rio de Janeiro、巴西
- 招聘中
- Hospital Universitário Pedro Ernesto
-
-
São Paulo
-
Ribeirão Preto、São Paulo、巴西
- 招聘中
- Hospital das Clínicas da FMRP-USP - Campus
-
São Paulo、São Paulo、巴西
- 招聘中
- Hospital das Clínicas da FMUSP
-
São Paulo、São Paulo、巴西
- 招聘中
- Hospital São Paulo - Hospital Universitário da UNIFESP
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adults aged 18 years or older with chronic rhinosinusitis or other sinonasal diseases and healthy volunteers without olfactory complaints, recruited at participating outpatient centers in Brazil.
描述
Inclusion Criteria:
Adults aged 18 years or older. Patients with chronic rhinosinusitis or other sinonasal diseases, or healthy volunteers without olfactory complaints participating in the comparison group.
Ability to understand and complete the study assessments.
Exclusion Criteria:
Illiteracy. Respiratory tract infection within the preceding seven days. Sinonasal surgery within the preceding six months. History of severe head trauma. Diagnosis of a neurodegenerative disease.
学习计划
研究是如何设计的?
设计细节
- 观测模型:OTHER
- 时间观点:CROSS_SECTIONAL
队列和干预
团体/队列 |
|---|
|
Sinonasal Disease Participants
Adults with chronic rhinosinusitis or other sinonasal diseases. |
|
Healthy Comparison Participants
Healthy adults without olfactory complaints. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
MultiScent-20 odor identification score
大体时间:Once at enrollment (cross-sectional assessment).
|
Total number of correctly identified odors on the 20-item MultiScent-20 digital odor identification test. Scores range from 0 to 20; higher scores indicate better odor identification performance. |
Once at enrollment (cross-sectional assessment).
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sinonasal Outcome Test-22 (SNOT-22) total score
大体时间:Once at enrollment (cross-sectional assessment).
|
Patient-reported sinonasal symptom burden assessed using the 22-item SNOT-22 questionnaire. Total scores range from 0 to 110; higher scores indicate greater symptom burden. |
Once at enrollment (cross-sectional assessment).
|
|
Severity of four sinonasal symptoms on visual analog scales
大体时间:Once at enrollment (cross-sectional assessment).
|
Severity will be assessed separately for nasal obstruction, rhinorrhea, facial pain or pressure, and olfactory dysfunction using four individual visual analog scales (VAS). Each score ranges from 0 (no symptoms) to 10 (maximum symptom intensity). Each symptom score will be analyzed in relation to the MultiScent-20 odor identification score. No combined VAS total score is prespecified. |
Once at enrollment (cross-sectional assessment).
|
|
Nasal Polyp Score (NPS)
大体时间:At enrollment, using available routine clinical assessment.
|
Endoscopic nasal polyp burden assessed using the Nasal Polyp Score, ranging from 0 to 8; higher scores indicate greater polyp burden. Applicable to participants with available endoscopic assessment. |
At enrollment, using available routine clinical assessment.
|
|
Lund-Mackay computed tomography score
大体时间:At enrollment; CT performed within the 12 months preceding enrollment, if available.
|
Extent of sinonasal opacification on computed tomography evaluated using the Lund-Mackay scoring system (total score 0-24; higher scores indicate more extensive radiologic disease). Assessed when routine-care imaging is available. |
At enrollment; CT performed within the 12 months preceding enrollment, if available.
|
|
Peripheral blood eosinophil count
大体时间:At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
|
Absolute peripheral blood eosinophil count obtained from available routine-care laboratory testing. |
At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
|
|
Total serum immunoglobulin E (IgE)
大体时间:At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
|
Total serum IgE concentration obtained from available routine-care laboratory testing. |
At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
|
|
Number of clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis
大体时间:Once at enrollment, using clinical data and available routine-care tests obtained within the preceding 12 months when applicable.
|
Count of predefined clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis, according to the guideline for use of biologics in chronic rhinosinusitis with nasal polyps cited in the study protocol. Clinical criteria: symptom onset between ages 30 and 50 years; marked improvement in olfaction following oral corticosteroid use; adult-onset asthma; aspirin or nonsteroidal anti-inflammatory drug intolerance; and bilateral nasal polyps associated with thick allergic- or eosinophilic-appearing nasal mucus, preferably confirmed by nasal endoscopy. Biomarker criteria: tissue eosinophils ≥10 cells/high-power field; blood eosinophils ≥250 cells/µL; or total serum IgE ≥100 IU/mL. The total number of criteria suggestive of type 2 inflammation will be calculated only for participants with complete data on all eight clinical and laboratory criteria. The count ranges from 0 to 8 and equals the number of positive criteria. |
Once at enrollment, using clinical data and available routine-care tests obtained within the preceding 12 months when applicable.
|
|
Presence of selected comorbidities
大体时间:Once at enrollment (cross-sectional assessment).
|
Presence or absence of relevant comorbidities, including asthma and aspirin-exacerbated respiratory disease (AERD), recorded from clinical history. |
Once at enrollment (cross-sectional assessment).
|
|
Number of previous sinonasal surgeries
大体时间:Once at enrollment (cross-sectional assessment).
|
The number of previous sinonasal surgeries will be recorded for each participant. |
Once at enrollment (cross-sectional assessment).
|
|
Alcohol intolerance
大体时间:Once at enrollment (cross-sectional assessment).
|
Alcohol intolerance will be assessed as a binary variable (yes/no), based on self-reported nasal symptoms following the consumption of alcoholic beverages. |
Once at enrollment (cross-sectional assessment).
|
合作者和调查者
调查人员
- 首席研究员:Gustavo Subtil M. Freire、University of Brasilia
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- UNB-OLFATO-RSC-2026
- 68687423.5.0000.5558 (其他标识符:Brazilian Research Ethics CAAE)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.